Axcella is designing and developing AXA Candidates, compositions of endogenous metabolic modulators, or EMMs, engineered in distinct ratios, designed to target and maximize the fundamental role that EMMs play in regulating multiple metabolic functions. Axcellaâs AXA Candidates are generated from its proprietary, human-focused AXA Development Platform. Axcella believes its expertise and capabilities in EMMs position it to become a preeminent biotechnology company reprogramming metabolism to address a diverse set of complex diseases and support health. Axcellaâs AXA Development Platform has already produced a pipeline of product candidates in programs targeting liver, muscle and blood. Axcella was founded by Flagship Pioneering. Source
No articles found.
Aquestive Therapeutics is a specialty pharmaceutical company that advances and com...
Aquestive Therapeutics is a specialty pharmaceu...
Ambu A/S engages in the development, production, and marketing of diagnostic and l...
Ambu A/S engages in the development, production...
Novanta is a leading global supplier of core technology solutions that give medica...
Novanta is a leading global supplier of core te...
RTI Surgical Holdings, Inc. is a leading global surgical implant company providing...
RTI Surgical Holdings, Inc. is a leading global...
Join the National Investor Network and get the latest information with your interests in mind.